ArticleCytotechnology2025
LncRNA NR2F1-AS1 is involved in osteogenic differentiation in fracture healing via miR-423-5p.
Article in Cytotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mesenchymal Stem/Stromal Cells-Derived Exosomal Micro-RNA Delivery Enhances Bone Repair in Osteoporotic Conditions.Tissue engineering. Part A · 2026Article
- Non-coding RNAs in osteoarthritis and osteoporosis-related hip fractures: molecular biomarkers for precision diagnosis and prognosis.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the function and mechanism of action of LncRNA NR2F1-AS1 involved in osteogenic differentiation process. An in vitro model was constructed by osteogenic differentiation-induced stimulation (OS) on the hFOB1.19 cell line. Real-time fluorescence quantitative PCR (RT-qPCR) was performed to detect the expression of NR2F1-AS1, miR-423-5p and osteogenic differentiation markers (RUNX2, OCN, OPN). Cell Counting Kit-8 (CCK8) method and flow cytometry were observed cell proliferation and apoptosis, respectively. Enzyme linked immunosorbent assay (ELISA) tested alkaline phosphatase (ALP) activity. Dual-Luciferase Report (DLR) assay and RNA immunoprecipitation (RIP) verified gene interactions. Bioinformatics methods predicted downstream target genes and their pathways of action. OS increased osteogenic differentiation markers and NR2F1-AS1 expression and decreased miR-423-5p levels. Transfection of si- NR2F1-AS1 promoted OS osteoblast apoptosis, but inhibited cell proliferation, ALP activity and osteogenic differentiation marker expression. NR2F1-AS1 is mostly present in the cytoplasm and is involved in the osteogenic differentiation process by down-regulating miR-423-5p. The use of miR-423-5p inhibitor can resist apoptosis induced by silencing NR2F1-AS1, promote osteoblast proliferation, activate ALP activity, and induce osteogenic differentiation process in osteoblasts. Bioinformatics prediction identified 82 target genes that might be involved in osteogenic differentiation, and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis suggested that they were mainly associated with inter-synaptic formation and signaling. NR2F1-AS1 may promote osteoblast proliferation stimulate ALP activity, and induce osteogenic differentiation by down-regulating miR-423-5p. Supplementary Information: The online version contains supplementary material available at 10.1007/s10616-025-00786-8.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.